RAPT THERAPEUTICS, INC. (RAPT): Price and Financial Metrics


0.98 (+4.09%)

POWR Rating

Component Grades













Add RAPT to Watchlist
Sign Up

Industry: Biotech



in industry


  • RAPT scores best on the Growth dimension, with a Growth rank ahead of 52.5% of US stocks.
  • RAPT's strongest trending metric is Value; it's been moving up over the last 177 days.
  • RAPT's current lowest rank is in the Momentum metric (where it is better than 3.9% of US stocks).

RAPT Stock Summary

  • RAPT's price/sales ratio is 211.59; that's higher than the P/S ratio of 98.66% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for RAPT THERAPEUTICS INC; that's greater than it is for just 8% of US stocks.
  • Revenue growth over the past 12 months for RAPT THERAPEUTICS INC comes in at -33.98%, a number that bests only 5.4% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RAPT THERAPEUTICS INC are QURE, BLU, XENE, IDYA, and BPMC.
  • Visit RAPT's SEC page to see the company's official filings. To visit the company's web site, go to www.rapt.com.

RAPT Valuation Summary

  • RAPT's price/sales ratio is 207.2; this is 10805.26% higher than that of the median Healthcare stock.
  • Over the past 35 months, RAPT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RAPT.

Stock Date P/S P/B P/E EV/EBIT
RAPT 2022-09-23 207.2 3.3 -8.8 -8.2
RAPT 2022-09-22 210.8 3.4 -9.0 -8.3
RAPT 2022-09-21 215.0 3.5 -9.2 -8.5
RAPT 2022-09-20 220.4 3.5 -9.4 -8.8
RAPT 2022-09-19 220.6 3.5 -9.4 -8.8
RAPT 2022-09-16 223.8 3.6 -9.5 -8.9

RAPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RAPT has a Quality Grade of D, ranking ahead of 15.97% of graded US stocks.
  • RAPT's asset turnover comes in at 0.034 -- ranking 343rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RAPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.034 1 -0.626
2021-03-31 0.043 1 -0.647
2020-12-31 0.037 1 -0.651
2020-09-30 0.030 1 -0.885
2020-06-30 0.020 1 -1.302
2019-12-31 0.000 NA 97.551

RAPT Price Target

For more insight on analysts targets of RAPT, see our RAPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.14 Average Broker Recommendation 1.43 (Moderate Buy)

RAPT Stock Price Chart Interactive Chart >

Price chart for RAPT

RAPT Price/Volume Stats

Current price $24.92 52-week high $40.74
Prev. close $23.94 52-week low $9.85
Day low $22.66 Volume 253,100
Day high $25.33 Avg. volume 318,609
50-day MA $24.45 Dividend yield N/A
200-day MA $22.19 Market Cap 739.05M


Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Latest News Stream

Event/Time News Detail
Loading, please wait...

RAPT Latest Social Stream

Loading social stream, please wait...

View Full RAPT Social Stream

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | September 23, 2022

Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Rapt Therapeutics (RAPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | September 23, 2022

Quite a few insiders invested in RAPT Therapeutics, Inc. (NASDAQ:RAPT) last year which is positive news for shareholders

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Yahoo | September 15, 2022

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | September 1, 2022

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September: Citi’s 17th Annual Biopharma Conference – In

Yahoo | August 31, 2022

Read More 'RAPT' Stories Here

RAPT Price Returns

1-mo -5.82%
3-mo 37.91%
6-mo 9.11%
1-year -22.97%
3-year N/A
5-year N/A
YTD -32.15%
2021 85.97%
2020 -28.47%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5834 seconds.